Recent advances in multidisciplinary approach for rectal cancer

International Journal of Clinical Oncology

Volumn 20, Issue 4, 2015, Pages 641-649

  Oki, Eiji ^a   Ando, Koji ^a   Kasagi, Yuta ^a   Zaitsu, Yoko ^a   Sugiyama, Masahiko ^a   Nakashima, Yuichiro ^a   Sonoda, Hideto ^a   Ohgaki, Kippei ^a   Saeki, Hiroshi ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Neoadjuvant chemoradiotherapy; Rectal cancer; Total mesorectal excision

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PANITUMUMAB;

ADJUVANT CHEMORADIOTHERAPY; HUMAN; LYMPH NODE DISSECTION; MESORECTAL EXCISION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECTUM CANCER; RECTUM SURGERY; REVIEW; TREATMENT PLANNING; ADJUVANT THERAPY; CHEMORADIOTHERAPY; MESENTERY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTAL NEOPLASMS; RECTUM;

CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MESENTERY; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; RECTUM;

EID: 84938748467     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0858-8     Document Type: Review

References (74)

1. Moser L, Ritz JP, Hinkelbein W et al (2008) Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer: a review focusing on open questions. Int J Colorectal Dis 23:227–236
2. Nussbaum N, Altomare I (2015) The neoadjuvant treatment of rectal cancer: a review. Curr Oncol Rep 17:434
3. Petrelli F, Coinu A, Lonati V et al (2015) A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis 30:447–457
4. Poulsen LO, Qvortrup C, Pfeiffer P et al (2015) Review on adjuvant chemotherapy for rectal cancer: why do treatment guidelines differ so much? Acta Oncol 54:437–446
5. Phang PT, Wang X (2014) Current controversies in neoadjuvant chemoradiation of rectal cancer. Surg Oncol Clin N Am 23:79–92
6. Kye BH, Cho HM (2014) Overview of radiation therapy for treating rectal cancer. Ann Coloproctol 30:165–174
7. Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696–701
8. Folkesson J, Birgisson H, Pahlman L et al (2005) Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23:5644–5650
9. Hamaguchi T, Shirao K, Moriya Y et al (2011) Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC). Cancer Chemother Pharmacol 67:587–596
10. Havenga K, DeRuiter MC, Enker WE et al (1996) Anatomical basis of autonomic nerve-preserving total mesorectal excision for rectal cancer. Br J Surg 83:384–388
11. Mori T, Takahashi K, Yasuno M (1998) Radical resection with autonomic nerve preservation and lymph node dissection techniques in lower rectal cancer surgery and its results: the impact of lateral lymph node dissection. Langenbecks Arch Surg 383:409–415
12. Sugihara K, Moriya Y, Akasu T et al (1996) Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome. Cancer (Phila) 78:1871–1880
13. Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg 69:613–616
14. van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582
15. Chua YJ, Barbachano Y, Cunningham D et al (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 11:241–248
16. Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646
17. Fujita S, Yamamoto S, Akasu T et al (2003) Lateral pelvic lymph node dissection for advanced lower rectal cancer. Br J Surg 90:1580–1585
18. Kinugasa T, Akagi Y, Shirouzu K (2014) Benefit of lateral lymph node dissection for rectal cancer: long-term analysis of 944 cases undergoing surgery at a single center (1975−2004). Anticancer Res 34:4633–4639
19. Moreira LF, Hizuta A, Iwagaki H et al (1994) Lateral lymph node dissection for rectal carcinoma below the peritoneal reflection. Br J Surg 81:293–296
20. De Felice F, Musio D, Izzo L et al (2014) Neoadjuvant chemoradiotherapy for locally advanced rectal cancer: the debate continues. World J Gastrointest Oncol 6:438–440
21. Roh MS, Yothers GA, O’Connell MJ et al (2011) The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29(suppl):abstr 3503
22. Gerard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30:4558–4565
23. Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644
24. Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780
25. Rodel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679–687
26. Rodel C, Arnold D, Becker H et al (2010) Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer: is it time for a randomized phase III trial? Strahlenther Onkol 186:658–664
27. Onyeuku NE, Ayala-Peacock DN, Russo SM et al (2015) The multidisciplinary approach to the treatment of rectal cancer: 2015 update. Expert Rev Gastroenterol Hepatol 9:507–517
28. Berho M, Narang R, Van Koughnett JA et al (2015) Modern multidisciplinary perioperative management of rectal cancer. JAMA Surg 150:260–266
29. Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284:1008–1015
30. Vaughan-Shaw P, Wheeler J, Borley N. (2015) The impact of a dedicated multidisciplinary team on the management of early rectal cancer. Colorectal Dis 87(10):5302–5309
31. Bonnetain F, Bosset JF, Gerard JP et al (2012) What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? Eur J Cancer 48:1781–1790
32. Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625
33. Bosset JF, Calais G, Mineur L et al (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results–EORTC 22921. J Clin Oncol 23:5620–5627
34. Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
35. Methy N, Bedenne L, Conroy T et al (2010) Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol 21:518–524
36. Roh MS, Colangelo LH, O’Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130
37. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740
38. Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13:579–588
39. Fernandez-Martos C, Pericay C, Aparicio J et al (2010) Phase II randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 28:859–865
40. Dewdney A, Cunningham D, Tabernero J et al (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30:1620–1627
41. Koyama M, Murata A, Sakamoto Y et al (2014) Long-term clinical and functional results of intersphincteric resection for lower rectal cancer. Ann Surg Oncol 21(Suppl 3):S422–S428
42. Portier G, Ghouti L, Kirzin S et al (2007) Oncological outcome of ultra-low coloanal anastomosis with and without intersphincteric resection for low rectal adenocarcinoma. Br J Surg 94:341–345
43. Saito N, Moriya Y, Shirouzu K et al (2006) Intersphincteric resection in patients with very low rectal cancer: a review of the Japanese experience. Dis Colon Rectum 49:S13–S22
44. Rullier E, Zerbib F, Laurent C et al (1999) Intersphincteric resection with excision of internal anal sphincter for conservative treatment of very low rectal cancer. Dis Colon Rectum 42:1168–1175
45. Schiessel R, Karner-Hanusch J, Herbst F et al (1994) Intersphincteric resection for low rectal tumours. Br J Surg 81:1376–1378
46. Sclafani F, Cunningham D (2014) Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Future Oncol 10:2243–2257
47. Schrag D, Weiser MR, Goodman KA et al (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32:513–518
48. Hasegawa J, Nishimura J, Mizushima T et al (2014) Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol 73:1079–1087
49. Uehara K, Hiramatsu K, Maeda A et al (2013) Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol 43:964–971
50. Weiser MR, Fichera A, Schrag D et al (2015) Progress in the PROSPECT trial: precision treatment for rectal cancer? Bull Am Coll Surg 100:51–52
51. Helbling D, Bodoky G, Gautschi O et al (2013) Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 24:718–725
52. Landry JC, Feng Y, Cohen SJ et al (2013) Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer (Phila) 119:1521–1527
53. Crane CH, Eng C, Feig BW et al (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76:824–830
54. Sadahiro S, Suzuki T, Tanaka A et al (2015) Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma. Oncology 88:49–56
55. Salazar R, Capdevila J, Laquente B et al (2015) A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer 15:60
56. Willett CG, Duda DG, Ancukiewicz M et al (2010) A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 15:845–851
57. Willett CG, Duda DG, di Tomaso E et al (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27:3020–3026
58. Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190
59. Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 25:1356–1362
60. Hong YS, Nam BH, Kim KP et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253
61. Yano H, Moran BJ (2008) The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg 95:33–49
62. Mortenson MM, Khatri VP, Bennett JJ et al (2007) Total mesorectal excision and pelvic node dissection for rectal cancer: an appraisal. Surg Oncol Clin N Am 16:177–197
63. Bell S, Sasaki J, Sinclair G et al (2009) Understanding the anatomy of lymphatic drainage and the use of blue-dye mapping to determine the extent of lymphadenectomy in rectal cancer surgery: unresolved issues. Colorectal Dis 11:443–449
64. Georgiou P, Tan E, Gouvas N et al (2009) Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol 10:1053–1062
65. Fujita S, Akasu T, Mizusawa J et al (2012) Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 13:616–621
66. Kato T, Ohashi Y, Nakazato H et al (2002) Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg. 386:575–581
67. Nakagoe T, Ishikawa H, Sawai T et al (2000) Multicenter randomized prospective study of adjuvant chemotherapy with UFT and mitomycin C in advanced colorectal cancer. Anticancer Res 20:1069–1075
68. Japan TCCCSGo (1995) Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan. Jpn J Clin Oncol 25:91–103
69. Oki E, Kakeji Y, Yoshida R et al (2006) A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC). Gan To Kagaku Ryoho 33(suppl 1):138–143
70. Murata A, Yoshida K, Maeda K, et al. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ASCO abstract #3515; 2015; 2015
71. 1997 Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med 336:980–987
72. Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701
73. Kusters M, Marijnen CA, van de Velde CJ et al (2010) Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol 36:470–476
74. Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933